{"id":"https://openalex.org/W2987080466","doi":"https://doi.org/10.1182/blood-2019-127506","title":"Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)","display_name":"Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2987080466","doi":"https://doi.org/10.1182/blood-2019-127506","mag":"2987080466"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-127506","doi":"https://doi.org/10.1182/blood-2019-127506","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-127506","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017380326","display_name":"Benjamin L. Lampson","orcid":"https://orcid.org/0000-0002-6033-3363","observed_orcids":["https://orcid.org/0000-0002-6033-3363"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin L. Lampson","raw_affiliation_strings":["Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010499534","display_name":"Svitlana Tyekucheva","orcid":"https://orcid.org/0000-0002-3119-6507","observed_orcids":["https://orcid.org/0000-0002-3119-6507"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Svitlana Tyekucheva","raw_affiliation_strings":["Department of Data Sciences, Department of Biostatistics, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Data Sciences, Department of Biostatistics, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088077600","display_name":"Jennifer Leigh Crombie","orcid":"https://orcid.org/0000-0003-3445-5129","observed_orcids":["https://orcid.org/0000-0003-3445-5129"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer L. Crombie","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017446407","display_name":"Austin Injae Kim","orcid":"https://orcid.org/0000-0003-1039-0658","observed_orcids":["https://orcid.org/0000-0003-1039-0658","https://orcid.org/0000-0002-9675-9374"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Austin I Kim","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065588144","display_name":"Reid W. Merryman","orcid":"https://orcid.org/0000-0002-6360-3234","observed_orcids":["https://orcid.org/0000-0002-6360-3234"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Reid W Merryman","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059821588","display_name":"Jessica Lowney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Lowney","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021158149","display_name":"Josie S. Montegaard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Josie Montegaard","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012072790","display_name":"Victoria Patterson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Victoria Patterson","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037526878","display_name":"Caron Alyce Jacobson","orcid":"https://orcid.org/0000-0002-0180-0654","observed_orcids":["https://orcid.org/0000-0002-0180-0654"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Caron A. Jacobson","raw_affiliation_strings":["Department of Medical Oncology, Dana Faber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana Faber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083104525","display_name":"Eric D. Jacobsen","orcid":"https://orcid.org/0000-0003-3014-0023","observed_orcids":["https://orcid.org/0000-0003-3014-0023"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric D Jacobsen","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085801543","display_name":"Ann Steward LaCasce","orcid":"https://orcid.org/0000-0001-7349-0176","observed_orcids":["https://orcid.org/0000-0001-7349-0176"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann S. LaCasce","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016770040","display_name":"Jon E. Arnason","orcid":"https://orcid.org/0000-0001-9038-7277","observed_orcids":["https://orcid.org/0000-0001-9038-7277"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jon E. Arnason","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Boston, MA","institution_ids":["https://openalex.org/I1316535847"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053410437","display_name":"Philippe A. Armand","orcid":"https://orcid.org/0000-0001-6098-1603","observed_orcids":["https://orcid.org/0000-0001-6098-1603"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philippe Armand","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101930428","display_name":"David Christopher Fisher","orcid":"https://orcid.org/0000-0001-6915-8584","observed_orcids":["https://orcid.org/0000-0001-6915-8584"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David C. Fisher","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer R. Brown","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":31,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"32","last_page":"32"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acalabrutinib","display_name":"acalabrutinib","score":0.9739999771118164},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9990000128746033},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":1.0},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9449999928474426},{"id":"https://openalex.org/keywords/previously-untreated-cll","display_name":"previously untreated CLL","score":0.9010000228881836},{"id":"https://openalex.org/keywords/bruton-tyrosine-kinase-inhibitors","display_name":"BTK inhibitors","score":0.7540000081062317},{"id":"https://openalex.org/keywords/time-limited-psychotherapy","display_name":"time-limited therapy","score":0.7329999804496765},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.4090000092983246},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6520000100135803},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.4449999928474426},{"id":"https://openalex.org/keywords/btk-inhibitor-resistance","display_name":"BTK inhibitor resistance","score":0.3269999921321869},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.5350000262260437},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.3100000023841858}],"concepts":[{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.8222746253013611},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.7950984239578247},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.7380636930465698},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7198952436447144},{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.6946351528167725},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5746150612831116},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5235112309455872},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.5167238116264343},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.5066081285476685},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.45519742369651794},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4489804208278656},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.42460864782333374},{"id":"https://openalex.org/C74133956","wikidata":"https://www.wikidata.org/wiki/Q4669824","display_name":"Absolute neutrophil count","level":4,"score":0.42322009801864624},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.3901814818382263},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38750654458999634},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.3710184395313263},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3530896306037903},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.33618271350860596},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.21508949995040894}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-127506","doi":"https://doi.org/10.1182/blood-2019-127506","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-127506","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3095558229","https://openalex.org/W4417006981","https://openalex.org/W4310124896","https://openalex.org/W3097014789","https://openalex.org/W3213981466","https://openalex.org/W4405035249","https://openalex.org/W3110997092","https://openalex.org/W4405034648","https://openalex.org/W4405049028","https://openalex.org/W2989438424"],"abstract_inverted_index":{"Backgound":[0],"Venetoclax":[1],"(V)":[2],"plus":[3],"obinutuzumab":[4,1063],"(O)":[5],"regimen":[6],"is":[7,91,290,324,363,454,692,760],"active":[8,94],"as":[9,68,95,390,669],"frontline":[10,670],"CLL":[11,107,158,176,671,1070],"treatment;":[12],"a":[13,86,119,131,315,419,675,695,771,949],"little":[14],"over":[15],"half":[16],"of":[17,34,49,61,73,123,134,153,226,244,251,317,327,424,467,472,594,630,638,660,666,678,698,738,860,878,892,906,1025],"patients":[18],"(pts)":[19],"will":[20,710,741],"achieve":[21,130],"undetectable":[22],"minimal":[23],"residual":[24],"disease":[25,388,488],"in":[26,155,283,303,382,396,401,408,557,573,752],"the":[27,47,70,140,147,253,277,304,325,445,714,734,749,753],"bone":[28,297],"marrow":[29,298],"(BM-uMRD)":[30],"with":[31,55,98,136,173,212,217,260,276,300,342,418,486,500,618,686,694],"one":[32,213],"year":[33],"time-limited":[35,120],"therapy":[36,281,423,661,672,1066],"(Fischer":[37],"et":[38,80,112],"al.":[39,81,113],"NEJM":[40],"2019).":[41],"Novel":[42],"strategies":[43],"may":[44,265],"further":[45,732],"augment":[46],"efficacy":[48,151,735],"VO.":[50],"Ibrutinib":[51],"was":[52,357,530],"previously":[53,102,156,174,1068],"combined":[54],"VO,":[56],"but":[57,606],"relatively":[58],"high":[59,132,676],"rates":[60],"infusion":[62,699],"reactions":[63,554,700],"and":[64,77,93,100,126,149,200,205,306,405,459,476,496,519,584,635,682,701,736,748],"neutropenia":[65,547,642],"were":[66,69,469,474,555,599,610,643],"observed,":[67],"characteristic":[71],"toxicities":[72],"ibrutinib":[74],"including":[75,296,684],"diarrhea":[76],"bruising":[78],"(Rogers":[79],"Blood":[82],"2018).":[83],"Acalabrutinib":[84],"(A),":[85],"more":[87,242],"selective":[88],"BTK":[89],"inhibitor,":[90],"well-tolerated":[92],"monotherapy":[96],"or":[97,640,705,862,880,894,908,1027],"O,":[99,252],"we":[101,143,725],"found":[103],"that":[104,118,287,650],"it":[105],"sensitizes":[106],"cells":[108],"to":[109,279,437,586,674,731,840,1056],"V":[110,234,614,626],"(Deng":[111],"Leukemia":[114],"2017).":[115],"We":[116],"hypothesized":[117],"triplet":[121,245],"combination":[122,1065],"A,":[124,203],"V,":[125,204],"O":[127,206,229,583],"(AVO)":[128],"could":[129],"rate":[133,326,443,697],"BM-uMRD":[135,284,328,481,681],"good":[137],"tolerability.":[138],"For":[139],"first":[141],"time":[142,421],"now":[144],"report":[145],"on":[146,415,422,604,616,721,856,874,888,902,1021],"safety":[148,737,996,1002],"preliminary":[150,647],"data":[152,351,648,709],"AVO":[154,246,668,740],"untreated":[157,175,1069],"pts.":[159,368,411],"Methods":[160],"This":[161],"ongoing":[162,718],"open-label,":[163],"single":[164],"arm,":[165],"phase":[166,754],"2":[167,224,497,574],"investigator-initiated":[168],"study":[169,362,416],"(NCT03580928)":[170],"enrolled":[171],"pts":[172,259,413,447,468,473,478,485,502,534,559,575,590,622,679,685],"without":[177],"restriction":[178],"by":[179,186,240,292,310,339,346,532],"prognostic":[180,378],"marker":[181],"status.":[182],"Eligibility:":[183],"requiring":[184],"treatment":[185],"iwCLL":[187,294,347],"criteria,":[188,295],"ECOG":[189],"PS":[190],"\u2264":[191],"2,":[192],"creatinine":[193],"clearance":[194],"\u226550ml/min,":[195],"absolute":[196],"neutrophil":[197],"count":[198],"\u2265500/mm3,":[199],"platelets":[201],"\u226530,000/mm3.":[202],"are":[207,337],"started":[208],"sequentially":[209],"(see":[210],"figure),":[211],"28-day":[214],"cycle":[215],"lead-in":[216],"A":[218],"at":[219,230,237,286,314,318,366,452,613,652,713],"100":[220],"mg":[221],"bid,":[222],"then":[223,233],"cycles":[225,243,435,659],"AO":[227],"(with":[228],"standard":[231],"dosing),":[232],"ramp-up":[235],"beginning":[236],"C4,":[238],"followed":[239],"3":[241,477,501,579,608,632,755],"therapy.":[247],"After":[248],"6":[249,434,493],"months":[250,426,665],"AV":[254,272,750],"doublet":[255,751],"continues":[256],"through":[257],"C15;":[258],"BM-uMRD-negative":[261],"CR":[262,285,329],"after":[263,330,433,581,657],"C15":[264],"discontinue":[266,280],"therapy,":[267],"while":[268],"all":[269,536],"others":[270],"continue":[271],"until":[273],"completing":[274],"C24,":[275],"option":[278],"if":[282],"time.":[288],"Response":[289],"assessed":[291,338],"2018":[293],"biopsy":[299],"MRD":[301],"testing":[302],"BM":[305],"peripheral":[307],"blood":[308],"(PB)":[309],"8-color":[311],"flow":[312],"cytometry":[313],"sensitivity":[316],"least":[319],"10-4.":[320],"The":[321,350,361,440,504,539,689],"primary":[322],"endpoint":[323],"15":[331],"cycles.":[332],"Non-hematologic":[333],"adverse":[334],"events":[335],"(AEs)":[336],"CTCAE":[340],"v5.0,":[341],"hematologic":[343],"toxicity":[344],"determined":[345],"criteria.":[348],"Results":[349],"cut":[352],"for":[353,444,602,625,716,1067],"this":[354,717],"interim":[355],"analysis":[356],"July":[358],"11,":[359],"2019.":[360],"fully":[364],"accrued":[365],"37":[367],"Median":[369],"age:":[370],"63":[371],"years":[372],"(range:":[373,427],"41-78),":[374],"73%":[375,523],"male.":[376],"Baseline":[377],"features:":[379],"unmutated":[380],"IGHV":[381],"23":[383],"(62%)":[384],"pts,":[385,399,404,596],"TP53":[386,394],"aberrant":[387],"(defined":[389],"either":[391],"del(17p)":[392],"and/or":[393],"mutation)":[395],"10":[397,402],"(27%)":[398,403],"del(11q)":[400],"complex":[406],"karyotype":[407],"7":[409],"(19%)":[410],"Thirty-six":[412],"remain":[414],"drugs":[417],"median":[420],"8":[425,484,558,658],"2-11).":[428],"One":[429,628],"pt":[430],"withdrew":[431],"consent":[432],"due":[436],"gastrointestinal":[438],"symptoms.":[439],"overall":[441],"response":[442,655],"24":[446],"who":[448,489],"have":[449,490,508,726],"completed":[450],"re-staging":[451],"C8":[453,464],"100%,":[455],"18":[456],"(75%)":[457],"PR":[458,495],"5":[460],"(25%)":[461],"CR.":[462],"At":[463],"restaging,":[465],"65%":[466],"PB-uMRD,":[470],"50%":[471],"BM-uMRD,":[475],"(13%)":[479],"had":[480,494,498],"CRs.":[482],"In":[483],"TP53-aberrant":[487,687],"reached":[491],"C8,":[492],"CR,":[499,683],"BM-uMRD.":[503],"most":[505,540],"frequent":[506,541],"AEs":[507],"been":[509,546],"fatigue":[510],"(81%":[511],"total,":[512,522,549],"78%":[513],"gr":[514,517,524,527,537,542,551,562,565,578,631],"1+2,":[515,525,563],"3%":[516,526,564],"\u22653)":[518],"headache":[520],"(76%":[521],"\u22653).":[528,552,566],"Bruising":[529],"reported":[531],"16":[533],"(43%,":[535],"1+2).":[538],"3/4":[543],"AE":[544,690],"has":[545],"(68%":[548],"32%":[550],"Infusion-related":[553],"seen":[556],"(22%,":[560],"19%":[561],"Laboratory":[567],"tumor":[568],"lysis":[569],"syndrome":[570],"(TLS)":[571],"occurred":[572],"(5%),":[576],"both":[577,589],"immediately":[580],"starting":[582],"prior":[585],"any":[587],"V;":[588],"continued":[591],"O.":[592],"Out":[593],"32":[595],"31":[597],"(97%)":[598],"medium-to-high":[600,611],"risk":[601,612,621],"TLS":[603],"C1D1":[605],"only":[607,663],"(9%)":[609],"initiation":[615],"C4D1,":[617],"4":[619,664],"medium-to-low":[620],"electively":[623],"admitted":[624],"initiation.":[627],"case":[629],"atrial":[633],"fibrillation":[634],"no":[636,702],"cases":[637],"hemorrhage":[639],"febrile":[641],"observed.":[644],"Conclusion":[645],"Our":[646],"suggest":[649],"even":[651],"an":[653,728,857,875,889,903,1022],"early":[654],"evaluation":[656],"(including":[662],"V),":[667],"leads":[673],"proportion":[677],"achieving":[680],"disease.":[688],"profile":[691],"favorable,":[693],"low":[696],"significant":[703],"cardiac":[704],"bleeding":[706],"toxicities.":[707],"Updated":[708],"be":[711,743],"presented":[712],"meeting":[715],"study.":[719],"Based":[720],"our":[722],"initial":[723],"results":[724],"opened":[727],"expansion":[729],"cohort":[730],"characterize":[733],"AVO.":[739],"also":[742],"studied":[744],"head-to-head":[745],"against":[746],"chemoimmunotherapy":[747],"trial":[756],"CL-311":[757],"(NCT03836261),":[758],"which":[759],"currently":[761],"enrolling.":[762],"Figure":[763],"Disclosures":[764],"Montegaard:":[765],"Pharmacyclics:":[766,823,974],"Consultancy;":[767,813,838,849,924,929,932,937,939,942,945,947,960,962,965,967,973,975,977,980,1039],"Janssen:":[768,989],"Consultancy.":[769,831,845,851,1006],"Jacobson:Kite,":[770],"Gilead":[772,950,1014],"Company:":[773,951],"Consultancy,":[774,782,788,792,797,803,808,827,834,853,871,886,900,952,956,969,982],"Honoraria,":[775,783,854,872],"Other:":[776,784,793,798,804,809,994,1000],"Travel":[777,785,794,799,805,810],"Expenses,":[778],"Research":[779,789,815,819,824,828,835,839,865,883,897,911,914,917,921,926,934,953,957,970,983,987,1053,1055],"Funding;":[780,790,816,820,825,829,836,884,898,912,915,918,922,927,954,958,971,984,988,1054],"Novartis:":[781,814,959],"Expenses;":[786,795,800,806],"Pfizer:":[787,928,972],"Humanigen:":[791,844],"Bayer:":[796],"Precision":[801],"Biosciences:":[802],"Celgene:":[807],"Expenses.":[811],"Jacobsen:Astra-Zeneca:":[812],"F.":[817],"Hoffmann-LaRoche:":[818],"Takeda:":[821],"Honoraria;":[822,990,992],"Merck:":[826],"Acerta:":[830],"LaCasce:Seattle":[832],"Genetics:":[833],"BMS:":[837],"Practice:":[841,1057],"Speakers":[842,867],"Bureau;":[843,868],"Arnason:Regeneron":[846],"Pharmaceuticals,":[847,1037],"Inc.:":[848],"Celgene/Juno:":[850],"Armand:Merck:":[852],"Membership":[855,873,887,901,1020],"entity's":[858,876,890,904,1023],"Board":[859,877,891,905,1024],"Directors":[861,879,893,907,1026],"advisory":[863,881,895,909,1028],"committees,":[864,882,896,910],"Funding,":[866],"Bristol-Myers":[869],"Squibb:":[870],"Adaptive:":[885],"Affimed:":[899],"Roche:":[913],"Otsuka:":[916],"Sigma":[919],"Tau:":[920],"Infinity:":[923],"Genentech:":[925],"ADC":[930],"Therapeutics:":[931,941,944,979],"Tensha:":[933],"Funding.":[935],"Brown:BeiGene:":[936],"AbbVie:":[938],"Catapult":[940],"Dynamo":[943],"Genentech/Roche:":[946],"Kite,":[948],"Loxo:":[955],"Juno/Celgene:":[961],"Acerta":[963,1008,1040],"Pharma:":[964],"AstraZeneca:":[966],"Gilead:":[968],"Sunesis:":[976],"TG":[978,1018,1050],"Verastem:":[981,1038,1052],"Sun":[985],"Pharmaceuticals:":[986],"Teva:":[991],"Morphosys:":[993],"Data":[995,1001],"monitoring":[997,1003],"board;":[998,1004],"Invectys:":[999],"Octapharma:":[1005],"Davids:AbbVie,":[1007],"Pharma,":[1009,1041,1043],"Adaptive,":[1010],"Biotechnologies,":[1011],"Astra-Zeneca,":[1012,1031],"Genentech,":[1013,1032,1044],"Sciences,":[1015],"Janssen,":[1016,1033],"Pharmacyclics,":[1017,1035,1047],"therapeutics:":[1019],"committees;":[1029],"AbbVie,":[1030],"MEI,":[1034],"Syros":[1036],"Ascentage":[1042],"MEI":[1045],"pharma,":[1046],"Surface":[1048],"Oncology,":[1049],"Therapeutics,":[1051],"Honoraria.":[1058],"OffLabel":[1059],"Disclosure:":[1060],"Acalabrutinib,":[1061],"venetoclax,":[1062],"-":[1064]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":12}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-11-22T00:00:00"}